Abbott has launched a new version of its Oncodetect molecular residual disease blood test, designed to look for small traces of cancer DNA during and after treatment. Announced on 26 October 2026, it uses a sample of a patient’s tumour to identify DNA changes to track in blood. This is a monitoring question in someone with a known cancer, rather than a screening test for people without a diagnosis. Abbott’s launch announcement
The new assay broadens the search for those traces. Understanding its value still requires three separate questions: how little DNA it can detect, how well a result predicts recurrence, and whether a treatment decision based on that result improves an outcome.
The tumour provides the starting pattern
Cancer cells can release DNA into the bloodstream. A tumour-informed test first profiles the patient’s tumour, then looks for matching changes in a blood sample. Molecular residual disease, usually shortened to MRD, refers to disease signals that may remain after treatment even when the molecular signal is very small.
Oncodetect’s new version combines whole-genome sequencing with MAESTRO, an enrichment method developed at the Broad Institute and enhanced by Abbott. Broad describes personalized probes that bind selected mutated DNA regions, allowing the laboratory to concentrate the tumour signal among much more abundant background DNA. Broad’s technology account
Abbott says the test can track up to 5,000 patient-specific variants, compared with up to 200 in its first-generation version. Those figures count possible molecular targets, rather than patients or health outcomes.
A detection limit is a laboratory measure
Abbott reports a limit of detection below one part per million under high-input conditions. That qualification matters: the claim concerns assay performance under specified sample conditions, rather than a guarantee that every patient’s cancer will leave a detectable signal.
The launch cites internal analytical presentations for parts of its detection-limit and specificity claims. Broad is a technology developer and commercial partner in this story, rather than an independent replication of Abbott’s performance assessment. The two announcements help explain the design and launch; their shared involvement stays relevant when interpreting the claims. Launch specifications and references
Analytical sensitivity, recurrence prediction and patient benefit concern different evidence. A more sensitive molecular assay can improve detection without, by that fact alone, establishing what treatment should follow.
One blood draw and repeated testing give different answers
A published esophageal-cancer study illustrates why the testing schedule belongs beside a sensitivity claim. Its abstract reports 331 plasma samples from 36 patients, collected before and after surgery. Those are repeated samples, not 331 different patients. We examined the abstract, not the full paper. Study abstract, Clinical Cancer Research
Among 14 patients who experienced recurrence and had postoperative plasma available, nine tested positive for circulating tumour DNA at their first postoperative sample. All 14 had at least one positive postoperative sample before recurrence when testing over time was considered.
The first result describes an early testing point. The second describes detection across multiple opportunities during follow-up. Presenting the latter as the sensitivity of a single postoperative blood test would lose that distinction. Neither finding means the test detected every future recurrence in a general cancer population.
The abstract supports a relationship between a postoperative molecular signal and recurrence in that study. It does not establish that changing care because of the signal improves survival. That requires evidence about the management strategy as well as the assay.
Availability and approval remain separate facts
The launch describes commercial availability for people with solid tumours, through a healthcare provider. It also explicitly states that the test has not been cleared or approved by the US FDA, and that performance characteristics may not apply to tumour types outside its clinical validation. The laboratory’s CLIA status is a different claim from FDA clearance of the test. Product scope and status
A commercial launch also does not establish payment coverage or local access in another country. The practical reading of this announcement is a new way of looking for patient-specific molecular traces during cancer follow-up, with assay, prognostic and treatment-outcome questions kept distinct.
For the different question of testing people without a cancer diagnosis, see our explanation of multi-cancer blood-test screening evidence.